Crescent Biopharma, Inc (CBIO) insider trading
Every open-market stock purchase and sale by Crescent Biopharma, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Joshua T Brumm (CEO) and 6 others sold $286K in the last 90 days.
- Last insider buy: Fairmount Funds Management LLC (10% owner), $12.4M, 3 months ago.
Last 12 months: insiders bought $40M (2 buys) and sold $1.5M (14 sales). Last close $13.17 on Oct 21, 2026.
Recent CBIO insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Sep 18, 2026 | Joshua T Brumm (CEO) | Sold | $131K |
| Sep 18, 2026 | Jonathan McNeill (COO) | Sold | $64.1K |
| Sep 16, 2026 | Joshua T Brumm (CEO) | Sold | $28.8K |
| Sep 16, 2026 | Jonathan McNeill (COO) | Sold | $13.1K |
| Sep 16, 2026 | Jan Pinkas (C-suite exec) | Sold | $11.8K |
| Sep 16, 2026 | Ellie Eunkyung Im (C-suite exec) | Sold | $11.2K |
| Sep 16, 2026 | Barbara Harlin Bispham (Officer) | Sold | $11.1K |
| Sep 16, 2026 | Richard William Scalzo (CFO) | Sold | $10.2K |
| Sep 16, 2026 | Ryan Lynch (Officer) | Sold | $4.3K |
| Jul 16, 2026 | Fairmount Funds Management LLC (10% owner) | Bought | $12.4M |
| Jul 16, 2026 | Fairmount Funds Management LLC (10% owner) | Bought | $7.6M |
| Jun 22, 2026 | Joshua T Brumm (CEO) | Sold | $761K |
| Jun 22, 2026 | Jonathan McNeill (COO) | Sold | $370K |
| Jun 22, 2026 | Jan Pinkas (C-suite exec) | Sold | $23.2K |
| Jun 22, 2026 | Ellie Eunkyung Im (C-suite exec) | Sold | $21.9K |
| Jun 22, 2026 | Barbara Harlin Bispham (Officer) | Sold | $21.9K |
| Jun 22, 2026 | Richard William Scalzo (CFO) | Sold | $20K |
| Jun 22, 2026 | Ryan Lynch (Officer) | Sold | $8.4K |
| Jun 2, 2026 | Susan Moran (Director) | Bought (not open market) | — |
| Jun 2, 2026 | Alexandra Balcom (Director) | Bought (not open market) | — |
| Jun 2, 2026 | Jonathan Violin (Director) | Bought (not open market) | — |
| Jun 2, 2026 | David Charles Lubner (Director) | Bought (not open market) | — |
| Jun 2, 2026 | Fairmount Funds Management LLC (10% owner) | Bought (not open market) | — |
| Dec 15, 2025 | Jan Pinkas (C-suite exec) | Bought (not open market) | — |
| Dec 15, 2025 | Christopher Grant Doughty (C-suite exec) | Bought (not open market) | — |
Who's trading CBIO
- Joshua T Brumm, CEO: sold $921K (3 sales), last Sep 18, 2026
- Jonathan McNeill, COO: sold $447K (3 sales), last Sep 18, 2026
- Richard William Scalzo, CFO: sold $30.2K (2 sales), last Sep 16, 2026
- Ellie Eunkyung Im, C-suite exec: sold $33.1K (2 sales), last Sep 16, 2026
- Ryan Lynch, Officer: sold $12.7K (2 sales), last Sep 16, 2026
- Barbara Harlin Bispham, Officer: sold $33K (2 sales), last Sep 16, 2026
- Jan Pinkas, C-suite exec: sold $34.9K (2 sales), last Sep 16, 2026
- Fairmount Funds Management LLC, 10% owner: bought $40M (4 buys), last Jul 16, 2026
- Jonathan Violin, Director: other filings, last Jun 2, 2026
- Alexandra Balcom, Director: other filings, last Jun 2, 2026
- David Charles Lubner, Director: other filings, last Jun 2, 2026
- Susan Moran, Director: other filings, last Jun 2, 2026
- Christopher Grant Doughty, C-suite exec: other filings, last Dec 15, 2025
Get free alerts when an insider at Crescent Biopharma, Inc files a new trade →